Clinical Trials Directory

We are doing this study to find out if an investigational drug called belumosudil (the study drug) is an option for the treatment of chronic lung allograft dysfunction (CLAD). The study drug is taken by mouth.

We are doing this study to understand how sex hormones (chemicals that tell cells and body parts to do certain things), such as estrogens and androgens, impact skin diseases like hidradenitis suppurativa (HS). To better understand this, we are enrolling both people who have diagnosed skin diseases and healthy volunteers who have no skin issues.

We are doing this study so that we can build a risk model that helps healthcare professionals better understand which children may have more trouble after a concussion. We collect data through surveys and saliva samples over the course of 1 year. Our ultimate goal is to improve recovery and support for kids with concussions.

We ask people questions to learn about their lives after a transplant. We want to know if they still have someone helping them after the first few months, if their job makes changes to help them, if money has been a problem, and what they plan to do about going back to work.

We are doing this study to find out if either of 2 different, experimental drug regimens (ramucirumab plus paclitaxel or FOLFIRI) is an option for treating small bowel cancer that has not responded to therapy.

We are doing this study to compare the early treatment (before you have cancer symptoms) of Venetoclax and Obitnutuzumab (V-O) to the usual treatment of V-O after you have cancer symptoms. This study will help doctors figure out if early treatment is better, the same, or worse than the usual approach of waiting until the patient has cancer symptoms before starting treatment.

We are doing this study to compare the usual treatment for neuroendocrine carcinomas to using atezolizumab plus the usual treatment. Another purpose is to compare using atezolizumab just at the beginning of treatment to continuing it beyond the initial treatment.

We are doing this study to compare two treatment options for PRCC. We want to know if adding an experimental drug called atezolimumab (the study drug) to the typical drug used in PRCC treatment, cabozantinib, can improve outcomes or extend survival time.